<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01980615</url>
  </required_header>
  <id_info>
    <org_study_id>PT010001-00</org_study_id>
    <nct_id>NCT01980615</nct_id>
  </id_info>
  <brief_title>Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind Within Device, Single-Dose, Four-Period, Six-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Three Doses of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), One Dose of Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (GFF MDI), and Two Doses of Symbicort® Inhalation Aerosol in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, Randomized, Double-Blind Within Device, Single-Dose, Four-Period,
      Six-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Three Doses of
      Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), One Dose of
      Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (GFF MDI), and Two Doses of
      Symbicort® Inhalation Aerosol in Healthy Volunteers. The primary objective of the study is to
      determine a dose of budesonide that when formulated with glycopyrronium and formoterol
      fumarate in BGF MDI provides comparable systemic exposure [pharmacokinetics (PK)] to
      budesonide following administration of Symbicort MDI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall safety of BGF, GFF, and Symbicort MDI based on the group of outcome measures for safety.</measure>
    <time_frame>12 hours following study drug administration</time_frame>
    <description>Safety of Three Doses of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), One Dose of Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (GFF MDI), and Two Doses of Symbicort Inhalation Aerosol.
The safety of BGF MDI, Symbicort MDI and GFF MDI will be assessed from physical examination findings, adverse event (AE) reporting including SAE reporting, vital signs (blood pressure, heart rate, respiratory rate and body temperature), clinical laboratory values (hematology, biochemistry, and urinalysis), and findings from 12-lead safety electrocardiograms (ECGs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall pharmacokinetic profile of BGF, GFF, and Symbicort MDI based on the group of outcome measures for pharmacokinetics.</measure>
    <time_frame>12 hours following study drug administration</time_frame>
    <description>Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), Symbicort MDI and GFF MDI.
The PK of BGF MDI, Symbicort MDI and GFF MDI will be assessed and compared from plasma concentrations of each drug.
PK parameters at all doses will include Cmax, tmax, t½, AUC0-12, AUC0-t, CL/F, Vd/F, and λz. Other PK parameters may be calculated, as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BGF MDI (PT010) Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGF MDI Dose 1 taken as 2 inhalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGF MDI (PT010) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGF MDI Dose 2 taken as 2 inhalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGF MDI (PT010) Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGF MDI Dose 3 taken as 2 inhalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GFF MDI (PT003) taken as 2 inhalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort MDI Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort MDI taken as 2 inhalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort MDI Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort MDI Dose 2 taken as 2 inhalations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled BGF (PT010) Dose 1</intervention_name>
    <arm_group_label>BGF MDI (PT010) Dose 2</arm_group_label>
    <arm_group_label>BGF MDI (PT010) Dose 3</arm_group_label>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 1</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled BGF (PT010) Dose 2</intervention_name>
    <arm_group_label>BGF MDI (PT010) Dose 1</arm_group_label>
    <arm_group_label>BGF MDI (PT010) Dose 3</arm_group_label>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 1</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled BGF (PT010) Dose 3</intervention_name>
    <arm_group_label>BGF MDI (PT010) Dose 1</arm_group_label>
    <arm_group_label>BGF MDI (PT010) Dose 2</arm_group_label>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 1</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled GFF (PT003)</intervention_name>
    <arm_group_label>BGF MDI (PT010) Dose 1</arm_group_label>
    <arm_group_label>BGF MDI (PT010) Dose 2</arm_group_label>
    <arm_group_label>BGF MDI (PT010) Dose 3</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 1</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Symbicort Dose 1</intervention_name>
    <arm_group_label>BGF MDI (PT010) Dose 1</arm_group_label>
    <arm_group_label>BGF MDI (PT010) Dose 2</arm_group_label>
    <arm_group_label>BGF MDI (PT010) Dose 3</arm_group_label>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Symbicort Dose 2</intervention_name>
    <arm_group_label>BGF MDI (PT010) Dose 1</arm_group_label>
    <arm_group_label>BGF MDI (PT010) Dose 2</arm_group_label>
    <arm_group_label>BGF MDI (PT010) Dose 3</arm_group_label>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_label>Symbicort MDI Dose 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide signed written informed consent form

          -  18 and 45 years (inclusive)

          -  Healthy subject confirmed by a thorough medical history and physical examination, ECG,
             vital signs and clinical laboratory tests

          -  Females of childbearing potential and males with female partners of childbearing
             potential must agree to use medically acceptable contraception

          -  Body mass index (BMI) between 18.5 and 32 kg/m2 (inclusive) and a minimum weight of 50
             kg at the screening visit

          -  Results of complete laboratory analyses should be within the normal range or
             determined to be not clinically significant by the Investigator

        Exclusion Criteria:

          -  Pregnancy, nursing female subjects, or subjects trying to conceive

          -  Clinically significant medical conditions

          -  History of ECG abnormalities

          -  Symptomatic prostatic hypertrophy, bladder neck obstruction, or urinary retention

          -  Known diagnosis of glaucoma

          -  Known or suspected history of substance-related disorders within 1 year of screening

          -  Treatment with an investigational drug within 30 days or five half-lives (whichever is
             longer) prior to screening period

          -  Hypersensitivity to lactose or any drug or component of the formulation(s) used in
             this study

          -  Positive screen for human immunodeficiency virus (HIV), hepatitis B surface antigen
             (HbsAg) or positive hepatitis C antibody at screening.

          -  Major surgery within four weeks or minor surgery within 2 weeks of drug administration

          -  Any other condition and/or situation that causes the Investigator to deem a subject
             unsuitable for study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>April 11, 2014</last_update_submitted>
  <last_update_submitted_qc>April 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

